Organogenesis Holdings Inc. Class A Common Stock Stock Prediction
AI-powered sentiment analysis and prediction trends for ORGO, updated each market day.
ORGO AI Sentiment
AI predicts Organogenesis Holdings Inc. Class A Common Stock stock is likely to decrease over the next 10 market days.
Prediction date: April 10, 2026
Subscribers see precise scores, buy/sell targets, and full analytics.
About Organogenesis Holdings Inc. Class A Common Stock
Organogenesis Holdings Inc is a regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the advanced wound care, surgical, and sports medicine markets. The company's portfolio of regenerative medicine products in the advanced wound care category includes Apligraf, Dermagraft, PuraPly AM, CYGNUS Dual, etc., and the sports medicine products include NuShield as a surgical barrier and PuraForce as a reinforcement matrix in targeted soft tissue repairs; and Affinity, Novachor, PuraPly MZ, PuraPly AM, and PuraPly SX for management of open wounds in the surgical setting. The company operates in a single segment, that is, regenerative medicine.
Sector
Exchange
Market Cap
$294,587,136
Cap Tier
Employees
854
Headquarters
CANTON, MA
Listed Since
Nov. 29, 2016
Website
ORGO Sentiment Trend — Last 30 Predictions
Sentiment zones: Bullish · Neutral · Bearish
ORGO Volatility
Organogenesis Holdings Inc. Class A Common Stock has shown high price volatility over the last 5 trading days. High volatility means larger price swings — this can present both opportunity and risk for traders.
